ClinicalTrials.gg
SuspendedNCT03623464Updated Sep 28, 2026

RCT of Mobile Apps & FitBit v. Usual Care

An interventional study of Mobile health application and Fitbit + standard of care and Standard of care in Pancreatic Cancer, Gastric Cancer and Hepatic Cancer, sponsored by Weill Medical College of Cornell University. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Other

How we know

Why this study was suspended
Study is paused for interim analysis.
Updated Sep 28, 2026Now SuspendedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University — none open to participants now, none under way, none of them phase 3. Pancreatic Neoplasms · Weill Medical College of Cornell University.

Started
2017
with 2 others
No phase
4 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University, this one is one of 3 that started in 2017, is one of 4 with no phase, and was the 8th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

None of the 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University is open now. The open studies under Pancreatic Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Pancreatic Neoplasms by Weill Medical College of Cornell University as a file.
02

Study summary

This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.

Read the detailed description

Patients will be randomized to 1) standard of care or 2) to use our mobile app with standard care. The mobile app will collect information on patients' daily physical activity patterns and health status data for clinicians using smartphone mobile technology applications. The investigators believe that by tracking information on patients, the investigators may be able to intervene sooner and prevent a delay in care.

03

Conditions studied

  • Pancreatic Cancer
  • Gastric Cancer
  • Hepatic Cancer
  • Colon Cancer
  • Rectal Cancer
  • Small Bowel Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 18 years or older
  2. Subject speaks English
  3. Subject owns a smart phone
  4. Subject is scheduled to undergo surgery for a GI cancer (pancreatic, hepatic, gastric, small bowel, colon, or rectal cancers)

Exclusion criteria

Exclusion Criteria:

  1. Physician deems the subject is unable to complete the study due to documented dementia
  2. Subject is undergoing emergent surgery
  3. Subject has sepsis from another source
  4. Physician deems the subject is unable to complete the study due to documented alcohol and/or drug abuse
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Active comparator
    Mobile app and Fitbit + Standard of care

    Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.

    Other: Mobile health application and Fitbit + standard of care

  • Other
    Standard of care

    Participants will receive standard of care

    Other: Standard of care

Interventions

  • OtherMobile health application and Fitbit + standard of care

    Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.

  • OtherStandard of care

    Post-operative standard of care information

06

What researchers measure

Primary outcomes

  1. Readmission rate

    Investigators will track readmission rates after surgery for those on the trial

    Time frame: 30 days

Secondary outcomes

  1. Healthcare utilization rates

    Investigators will track patients' healthcare resource utilization and the cost of this utilization by assessing how often the patients contact their providers via phone or the app, access the emergency room, and through readmission data.

    Time frame: 30 days

  2. Patient Satisfaction with Device

    Investigators will assess patients' satisfaction with their care experience and device. This will be done with an internal questionnaire asking if patients were satisfied and if they found it easy to use.

    Time frame: 30 days

  3. Quality of life: Return to Baseline Function-Walking

    Investigators will monitor patients' return to baseline health after surgery by tracking progress via step counts, as monitored by a FitBit tracker.

    Time frame: 30 days

  4. Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)

    Investigators will monitor patients' return to baseline health after surgery by tracking progress using a questionnaire, modified from the Katz Activities of Daily Living scale. For this scale, a score of 6 is high, indicating that the patient is independent and a score of 0 is low, indicating that the patient very dependent in performing their ADLs.

    Time frame: 30 days

07

Study locations

1 site
  • Weill Cornell Medicine- New York Presbyterian
    New York, New York 10021, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2017 (actual). Primary completion is estimated for Mar 2027, 118 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2026 → Mar 2027 and completion Jun 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2017
First posted
Aug 9, 2018
StartActual
May 31, 2017
Primary completionEst.
Mar 2027was Jun 2026
CompletionEst.
Mar 2027was Jun 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Suspended Study is paused for interim analysis.
changed Sep 28, 2026
Primary completion
Jun 2026→Mar 2027
Sep 28, 2026
Study completion
Jun 2026→Mar 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Active, not recruiting→Suspended
    Why stopped Study is paused for interim analysis.
    Primary completion Jun 2026→Mar 2027
    Study completion Jun 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03623464
Collaborators
Damon Runyon Cancer Research Foundation
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
May 31, 2017
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Heather Yeo, MD
principal investigator · Weill Medical College of Cornell University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion